Shots:
- The US FDA granted 510(k) clearance to the UB ERP System for electroencephalography & event-related potentials-based brain function assessment, with commercial launch expected later this year
- To support clinical expansion, the company initiated US & Japan studies in depression to evaluate brain function before & after 1L antidepressant treatment, and develop objective brain function markers associated with treatment response, respectively
- Also, Universal Brain secured a $2M grant from the Japan Agency for Medical Research and Development to support multi-site clinical studies and commercialization under its Next-Generation Medical Device Development Project
Ref: Businesswire | Image: Universal Brain | Press Release
R
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
